N4 Pharma PLC Positive Covid-19 In Vitro Study Results (9549V)
12 Agosto 2020 - 7:47AM
UK Regulatory
TIDMN4P
RNS Number : 9549V
N4 Pharma PLC
12 August 2020
12 August 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Positive Covid-19 In Vitro Study Results
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce that Nuvec(R) loaded with
Coronavirus plasmid has successfully transfected Human Embryonic
Kidney ("HEK") cells in vitro and induced an expression of the
spike protein in the cells.
This successful result is the second stage of the Company's
three stage plan for its Covid-19 proof of concept research project
being undertaken with Evotec International Gmbh ("Evotec") means
that the project will now move into its third stage, being the pre
in vivo study to demonstrate expression of the spike protein in
target cells in a murine target.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"We are delighted to have achieved in vitro transfection of HEK
cells with Nuvec(R) loaded with coronavirus plasmid. We now move
straight to the third stage of our Covid-19 project with our pre in
vivo study at Evotec. The global pandemic continues to dominate all
of our lives and we are extremely excited to be moving onto the
next stage of our Covid-19 project, the successful outcome of which
will determine our next work streams in this area and how we might
collaborate with appropriate partners interested in any advantage
our Nuvec(R) delivery system may provide. We look forward to
providing updates on this project and our other work streams in due
course."
Clarification note
In the Company's announcement of 16 April 2020, it stated the
original intention to use murine peripheral blood mononuclear
("PBMC") cells for the in vitro study. However, when working with
the PBMCs it was not possible to get a sufficient number to
undertake all the experiments. As a result the in vitro work was
done using HEK cells as detailed above.
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via Scott PR
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
Scott PR
Georgia Smith Tel: +44(0)1477 539
539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSFIFEEESSELA
(END) Dow Jones Newswires
August 12, 2020 08:47 ET (12:47 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024